Antibiotic resistance is already costing US hospitals about $7.7 to $11.8 billion every year in extra care, even as infections keep tightening their grip. Worldwide, AMR was responsible for 1.27 million deaths in 2019, and when adjusted for underreporting the impact rises to 68% more, with projections reaching 10 million deaths annually by 2050 if current trends continue.
Key Takeaways
- AMR costs US hospitals $7.7-11.8 billion yearly in extra care
- Global AMR economic burden estimated at $5-24 billion annually in direct costs
- EU/EEA AMR healthcare costs exceed €1.5 billion yearly
- In 2019, bacterial antimicrobial resistance (AMR) was directly responsible for 1.27 million deaths worldwide, with an additional 4.95 million deaths associated with AMR
- AMR accounted for 15% of all deaths among children under 5 years old in 2019 globally
- Global deaths from AMR increased by 68% from 1.27 million in 2019 estimates when adjusted for underreporting
- In US hospitals, AMR leads to 35,000 deaths annually from 2.8 million infections
- Prolonged hospital stays due to AMR average 7-14 extra days per patient
- AMR infections increase ICU admission risk by 2-4 fold
- In the US, Clostridioides difficile causes 15,000 deaths yearly from AMR strains
- Globally, 80% of MRSA infections are healthcare-associated
- Vancomycin-resistant Enterococcus (VRE) affects 54,000 patients annually in US hospitals
- In Europe, AMR causes over 33,000 deaths annually
- US sees 2.8 million AMR infections yearly, leading to 35,000 deaths
- In the EU/EEA, 670,000 AMR infections occur annually, with 33,000 attributable deaths
AMR already kills millions and costs tens of billions yearly, with deaths projected to surge by 2050.
Related reading
01 · Category
Economic And Policy Implications23 stats
01
AMR costs US hospitals $7.7-11.8 billion yearly in extra care
02
Global AMR economic burden estimated at $5-24 billion annually in direct costs
03
EU/EEA AMR healthcare costs exceed €1.5 billion yearly
04
Lost productivity from AMR projected at $3.4 trillion by 2050 globally
05
US spends $20 billion annually on treating 2.8 million AMR infections
06
Stewardship programs reduce AMR costs by 20-50% in hospitals
07
New antibiotics R&D investment needed: $40 billion over 10 years
08
AMR threatens $1 trillion in GDP losses by 2050 in LMICs
09
UK invests £2 billion in AMR national action plan 2019-2024
10
Global surveillance (GLASS) covers 80 countries but needs $100 million yearly funding
11
Vaccine development could avert $8 billion in AMR costs by 2050
12
Policy gaps lead to 50% inappropriate antibiotic prescribing in primary care
13
Rapid diagnostics could save $4.5 billion in US hospital costs yearly
14
Animal agriculture antibiotic use bans in EU saved €200 million in human health costs
15
Global Fund invests $1 billion in AMR diagnostics and surveillance
16
China’s AMR action plan 2022-2025 allocates 10 billion yuan for control measures
17
One Health approach could reduce global AMR costs by 30%
18
Patent incentives for new antibiotics need $1 billion market entry rewards
19
Community antibiotic overuse costs $1.7 billion yearly in US prescriptions
20
International coordination via UN could prevent $10 trillion cumulative losses by 2050
21
Global AMR treatment costs $21 billion yearly in excess healthcare
22
EU policy reduced antibiotic consumption by 20% from 2010-2020, saving lives
23
US national action plan targets 20% reduction in hospital antibiotic use by 2020
Interpretation
Economic And Policy Implications Interpretation
Economic and policy responses to antibiotic resistance are urgent because treating AMR now costs US hospitals $7.7–11.8 billion a year and the global productivity loss could reach $3.4 trillion by 2050, yet hospital stewardship programs can cut these costs by 20–50 percent.
02 · Category
Global Burden25 stats
01
In 2019, bacterial antimicrobial resistance (AMR) was directly responsible for 1.27 million deaths worldwide, with an additional 4.95 million deaths associated with AMR
02
AMR accounted for 15% of all deaths among children under 5 years old in 2019 globally
03
Global deaths from AMR increased by 68% from 1.27 million in 2019 estimates when adjusted for underreporting
04
By 2050, AMR could cause 10 million deaths annually if trends continue unchecked
05
In 2019, AMR was responsible for 1.27 million direct deaths, comparable to deaths from HIV/AIDS and malaria combined
06
The global burden of AMR in 2019 led to 495 million Disability-Adjusted Life Years (DALYs) lost
07
AMR-associated deaths reached 5 million in 2019, with 74.3% occurring in low- and middle-income countries (LMICs)
08
From 1990 to 2019, AMR death rates increased by 18% globally, from 18.2 to 21.4 per 100,000
09
In 2021, WHO estimated that AMR could undermine 25 years of progress in reducing child mortality
10
Global AMR burden in 2019 was highest for methicillin-resistant Staphylococcus aureus (MRSA) at 570,000 deaths
11
AMR caused 4.47 million deaths in sub-Saharan Africa in 2019, representing 25% of global AMR-associated deaths
12
Worldwide, 20-50% of antibiotics are used inappropriately in hospitals, contributing to AMR burden
13
In low-income countries, AMR contributes to 700,000 deaths annually from resistant infections
14
Global economic cost of AMR projected at $100 trillion by 2050 due to healthcare and productivity losses
15
AMR leads to 35 million deaths projected by 2050 if no action taken
16
In 2019, six pathogen-drug combinations accounted for 92% of AMR-associated deaths globally
17
Global AMR death rate in 2019 was 20.6 per 100,000 population
18
AMR burden disproportionately affects South Asia with 1.28 million deaths in 2019
19
From 2019 to 2022, global AMR deaths rose by 15% post-COVID
20
WHO lists AMR as one of top 10 global health threats, impacting 1.27 million direct deaths yearly
21
In 2019, South Asia had the highest age-standardized AMR death rate at 56.6 per 100,000
22
High-income North America saw 26.6 AMR deaths per 100,000 in 2019
23
Global DALYs from AMR rose 15% from 2010 to 2019
24
AMR exacerbates 769,000 HIV-related deaths annually indirectly
25
11 million deaths projected avertable by 2050 with interventions
Interpretation
Global Burden Interpretation
In the global burden of antibiotic resistance, 1.27 million deaths in 2019 were projected to grow by 68% when adjusted for underreporting and could reach 10 million deaths annually by 2050 if current trends continue unchecked.
03 · Category
Healthcare Impacts26 stats
01
In US hospitals, AMR leads to 35,000 deaths annually from 2.8 million infections
02
Prolonged hospital stays due to AMR average 7-14 extra days per patient
03
AMR infections increase ICU admission risk by 2-4 fold
04
70% of US hospital-acquired infections involve resistant bacteria
05
Treatment failure rates for resistant UTIs reach 50% with first-line antibiotics
06
AMR contributes to 25% of sepsis deaths in hospitals worldwide
07
Post-surgical infections from resistant pathogens delay recovery by 20 days on average
08
In ICUs, 50% of ventilator-associated pneumonia cases are multidrug-resistant
09
Neonatal sepsis mortality from resistant bacteria is 24% in LMICs
10
Catheter-associated UTIs have 30% resistance to standard prophylaxis
11
AMR raises dialysis infection risks, with 15% involving MRSA
12
Cancer patients face 40% higher mortality from AMR bacteremia
13
20% of bloodstream infections in hospitals are CRE, with 50% mortality
14
Transplant patients have 10-fold higher AMR infection rates
15
Elderly care facilities report 60% colonization with resistant Enterobacterales
16
Emergency department sepsis from AMR has 30% treatment escalation rate
17
Pediatric AMR pneumonia hospitalization rates up 15% since 2010
18
AMR in wound infections prolongs healing by 2 weeks on average
19
HIV patients with AMR TB have 50% worse outcomes
20
Hospital AMR lengthens stays by 13 days for pneumonia
21
75% of US nursing home infections are antibiotic-resistant
22
AMR sepsis doubles mortality risk to 40%
23
Pediatric ICU AMR rates tripled since 2005
24
Orthopedic implant infections from MRSA recur in 30% of cases
25
AMR raises chemotherapy complication rates by 25%
26
Burn unit AMR infections affect 60% of patients
Interpretation
Healthcare Impacts Interpretation
Within healthcare systems, antibiotic resistance is driving major harm, causing about 35,000 deaths each year in US hospitals and adding 7 to 14 extra hospital days per patient while also raising ICU admission risk by 2 to 4 times.
More related reading
04 · Category
Pathogen Specific Resistance30 stats
01
In the US, Clostridioides difficile causes 15,000 deaths yearly from AMR strains
02
Globally, 80% of MRSA infections are healthcare-associated
03
Vancomycin-resistant Enterococcus (VRE) affects 54,000 patients annually in US hospitals
04
Carbapenem-resistant Enterobacterales (CRE) have 13,100 cases and 1,100 deaths yearly in US
05
Multidrug-resistant TB (MDR-TB) causes 450,000 cases globally each year
06
ESBL-producing E. coli show 50-70% resistance to third-generation cephalosporins worldwide
07
Acinetobacter baumannii resistant to carbapenems in 90% of US cases
08
Pseudomonas aeruginosa carbapenem resistance at 20-40% in ICU settings globally
09
Neisseria gonorrhoeae shows >5% resistance to third-generation cephalosporins in 40 countries
10
Salmonella Typhi extensively drug-resistant (XDR) in 10% of Pakistani cases
11
Klebsiella pneumoniae carbapenem-resistant in 30% of global bloodstream infections
12
Streptococcus pneumoniae penicillin non-susceptibility at 30% in some Asian countries
13
Campylobacter jejuni shows 24% ciprofloxacin resistance in US
14
Candida auris has 90% resistance to fluconazole in some outbreaks
15
Mycobacterium leprae dapsone resistance in 5-10% of new leprosy cases globally
16
Escherichia coli fluoroquinolone resistance reached 80% in some EU countries by 2022
17
Haemophilus influenzae ampicillin resistance at 20% in children globally
18
Shigella sonnei azithromycin resistance emerging at 15% in travelers
19
Listeria monocytogenes resistance to ampicillin rare but increasing to 5% in food isolates
20
In US, community MRSA accounts for 20,000 deaths yearly
21
Globally, 2.4 million people develop drug-resistant TB yearly
22
CRE mortality rate is 40% in bloodstream infections
23
VRE bacteremia has 30% attributable mortality
24
85% of gonorrhea cases in Western Pacific are azithromycin-resistant
25
C. auris mortality reaches 30-60% in invasive infections
26
40% of hospital Klebsiella are carbapenem-resistant in US
27
MDR Acinetobacter causes 9,000 US deaths yearly
28
Fluoroquinolone-resistant Salmonella in 27% of US cases
29
Penicillin-resistant pneumococcus in 25% of invasive US cases
30
ESBL E. coli in 13% of EU bloodstream infections
Interpretation
Pathogen Specific Resistance Interpretation
Pathogen specific resistance is already driving major, measurable harm, from 15,000 annual US deaths linked to resistant Clostridioides difficile to 13,100 yearly US CRE cases with 1,100 deaths and 450,000 global MDR TB cases each year.
05 · Category
Regional Variations27 stats
01
In Europe, AMR causes over 33,000 deaths annually
02
US sees 2.8 million AMR infections yearly, leading to 35,000 deaths
03
In the EU/EEA, 670,000 AMR infections occur annually, with 33,000 attributable deaths
04
India reports 58% resistance to third-generation cephalosporins in E. coli from community settings
05
Sub-Saharan Africa has the highest AMR death rate at 27.3 per 100,000 in 2019
06
In Latin America, AMR-associated mortality rate is 42 per 100,000, higher than Europe
07
China experiences 1.1 million AMR-associated deaths yearly
08
Australia reports 2,000 AMR deaths annually, with rising carbapenem-resistant Enterobacterales
09
In Southeast Asia, 38% of Klebsiella pneumoniae are resistant to carbapenems
10
Western Pacific region sees 25% increase in AMR infections from 2015-2020
11
UK has 5,000-10,000 AMR deaths per year, with 1 in 5 E. coli infections resistant to first-line antibiotics
12
In the US, 48,000 hospital-onset AMR infections in 2019
13
Canada reports 14,000 AMR infections annually
14
Brazil has 73,000 AMR deaths yearly
15
Russia sees high rates of multidrug-resistant TB at 28% of new cases
16
Middle East and North Africa have 21% carbapenem resistance in Acinetobacter
17
In Japan, MRSA prevalence in bloodstream infections is 52%
18
South Korea reports 70% fluoroquinolone resistance in E. coli UTIs
19
Nigeria has 80% resistance to ampicillin in Salmonella Typhi
20
Oceania has lowest AMR burden at 12.5 deaths per 100,000
21
Eastern Europe reports 40 deaths per 100,000 from AMR
22
In Africa, 27% of neonatal sepsis cases are AMR
23
Mexico sees 70% resistance to ciprofloxacin in gonorrhea
24
In the EU, third-generation cephalosporin resistance in E. coli is 17.3%
25
Pakistan has 90% ceftriaxone resistance in XDR typhoid
26
Vietnam reports 50% colistin resistance in CRE
27
Germany has MRSA bacteremia rate of 7 per 100,000
Interpretation
Regional Variations Interpretation
Regional variations are stark, with Sub Saharan Africa leading AMR deaths at 27.3 per 100,000 in 2019 while the US records 2.8 million infections and 35,000 deaths each year and Europe sees over 33,000 annual deaths, alongside higher resistance in India and elevated mortality in Latin America at 42 per 100,000.
report visual · Breakdown
The human and economic burden of AMR
AMR is driving major mortality while also creating substantial costs for healthcare systems and society.
50%
Policy gaps lead to 50% inappropriate antibiotic prescribing in primary care
50%
Treatment failure rates for resistant UTIs reach 50% with first-line antibiotics
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Antibiotic Resistance Statistics. Gitnux. https://gitnux.org/antibiotic-resistance-statistics
MLA
Rachel Svensson. "Antibiotic Resistance Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/antibiotic-resistance-statistics.
Chicago
Rachel Svensson. 2026. "Antibiotic Resistance Statistics." Gitnux. https://gitnux.org/antibiotic-resistance-statistics.
Sources & references
17 datasets cited across this report · attribution is report-level